- Home
- FN vs LEGN Comparison
FN vs LEGN Comparison
Compare FN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FN
- LEGN
- Stock Information
- Founded
- FN 1999
- LEGN 2014
- Country
- FN Cayman Islands
- LEGN United States
- Employees
- FN N/A
- LEGN N/A
- Industry
- FN Telecommunications Equipment
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- FN Utilities
- LEGN Health Care
- Exchange
- FN Nasdaq
- LEGN Nasdaq
- Market Cap
- FN N/A
- LEGN 7.0B
- IPO Year
- FN 2010
- LEGN 2020
- Fundamental
- Price
- FN $196.12
- LEGN $35.06
- Analyst Decision
- FN Buy
- LEGN Strong Buy
- Analyst Count
- FN 8
- LEGN 13
- Target Price
- FN $247.88
- LEGN $79.17
- AVG Volume (30 Days)
- FN 900.4K
- LEGN 1.1M
- Earning Date
- FN 05-05-2025
- LEGN 03-11-2025
- Dividend Yield
- FN N/A
- LEGN N/A
- EPS Growth
- FN 29.03
- LEGN N/A
- EPS
- FN 8.94
- LEGN N/A
- Revenue
- FN $3,122,632,000.00
- LEGN $627,241,000.00
- Revenue This Year
- FN $20.88
- LEGN $66.60
- Revenue Next Year
- FN $13.11
- LEGN $49.28
- P/E Ratio
- FN $21.94
- LEGN N/A
- Revenue Growth
- FN 14.83
- LEGN 119.97
- 52 Week Low
- FN $159.69
- LEGN $30.17
- 52 Week High
- FN $281.79
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- FN 41.25
- LEGN 44.07
- Support Level
- FN $215.24
- LEGN $34.00
- Resistance Level
- FN $235.60
- LEGN $36.20
- Average True Range (ATR)
- FN 10.87
- LEGN 1.52
- MACD
- FN -0.83
- LEGN -0.25
- Stochastic Oscillator
- FN 18.79
- LEGN 25.18
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.